CA
NZ
UK
AU
IND
US
Adaptive Biotechnologies (NASDAQ:ADPT) shares held near fresh 52-week highs in pre-market trading Thursday after a multi-day rally built on strong clinical and commercial momentum in the company's Minimal Residual Disease testing franchise. Adaptive Biotechnologies is a Seattle-based commercial-stage biotechnology company that leverages a proprietary …
DexCom (NASDAQ:DXCM) has helped transform how people with diabetes manage their condition, replacing painful finger-prick tests with small sensors that track glucose continuously. As that technology spreads to more people, glucose-monitoring adoption has become a crucial healthcare theme forNasdaq100 investors, with a large and …
GE HealthCare (NASDAQ:GEHC) makes the scanners that hospitals use to see inside the human body, and it is now adding artificial intelligence to make those machines smarter and more useful. As hospitals invest in imaging and adopt AI, GE HealthCare offersNasdaq100 investors aBusinessstory rooted …
Gilead Sciences (NASDAQ:GILD) owes its position to a single therapeutic area it has dominated for decades, HIV, and its future depends on defending that franchise while proving it can grow beyond it. ForNasdaq100 investors, the twin questions of how well its HIV business holds …
● Gossamer Bio plans to submit an NDA for seralutinib in pulmonary arterial hypertension in September 2026, backed by Phase 3 PROSERA and Phase 2 TORREY data.
IDEXX Laboratories (NASDAQ:IDXX) has built a highly profitableBusinessout of a simple trend: people increasingly treat their pets as family and spend accordingly on their health. As the leader in veterinary diagnostics, IDEXX makes pet testing a distinctive and durable growth theme within theNasdaq100.
Intuitive Surgical (NASDAQ:ISRG) sells expensive robotic systems that help surgeons operate, but the real engine of itsBusinessis not the machines themselves: it is the number of procedures performed on them. Because the company earnsRecurring Revenueevery time a surgeon uses one of its robots, procedure …
● Nano-X Imaging posted 37%Revenuegrowth alongside aGAAPnet loss of $55.5 million driven by a $40.7 millionImpairmentcharge.
Regeneron (NASDAQ:REGN) has built a formidableBusinesson a handful of blockbuster medicines, but its future depends on what comes next. As its older products face growing competition, pipeline progress, turning laboratory science into approved, saleable drugs, is crucial to itsNasdaq100 healthcare story.
● Synergy CHC disclosed aNasdaqnotice on 20 August 2026 for failing to timely file its Form 10-Q for the quarter ended 30 June 2026, with a compliance plan due by 19 October 2026.
Please wait processing your request...